pharmaceuticals
pharmaceuticals Articles
Tetraphase Pharmaceuticals saw its shares get cut in half on Wednesday after the firm provided an update on its late-stage clinical trial for the treatment of urinary tract infections.
Published:
Last Updated:
Catabasis Pharmaceuticals saw its shares skyrocket on Tuesday after the firm announced new results from its Duchene muscular dystrophy study with edasalonexent.
Published:
Last Updated:
The January 31 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Published:
Last Updated:
Demand for two Ford SUVs will cause an increase in production, a major pharmaceutical company said it will stop marketing opioids to physicians, and other important headlines.
Published:
Last Updated:
Four large-cap pharmaceutical leaders are rated Overweight at JPMorgan, and all make sense for growth accounts looking for some safety and income.
Published:
Last Updated:
Theravance Biopharma shares made a solid gain on Wednesday after the company announced a global collaboration with Janssen Biotech.
Published:
Last Updated:
Though Allergan reported better than expected quarterly results before the markets opened on Tuesday, its shares retreated.
Published:
Last Updated:
Fourth-quarter and full-year earnings at Bristol-Myers Squibb beat estimates, but a report of the successful trial of the company's lung cancer treatment may be the big mover for the stock Monday.
Published:
Last Updated:
24/7 Wall St. has included a calendar of a some of the biggest companies expecting clinical trial and U.S. Food and Drug Administration (FDA) updates in February.
Published:
Last Updated:
Merck reported mixed fourth-quarter financial results before the markets opened on Friday.
Published:
Last Updated:
Eli Lilly reported better-than-expected fourth-quarter financial results before the markets opened on Wednesday.
Published:
Last Updated:
Pharmaceuticals giant Pfizer beat quarterly and full-year expectations this morning, but the beats were small and the forecast for next year is not exhilarating.
Published:
Last Updated:
This year is shaping up to be a stellar one for biotech. Investors are looking for growth and upside, and that can drive the interest in biotechs ever higher.
Published:
Last Updated:
AbbVie reported better-than-expected fourth-quarter financial results before the markets opened on Friday.
Published:
24/7 Wall St. has noticed that analysts and investors seem to not be able to get enough of Abbott Laboratories.
Published:
Last Updated: